Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the Zucker diabetic fatty rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 3, 2005, Pages 1020-1027

  Johns, Douglas G ^a   Ao, Zhaohui ^a   Eybye, Marianne ^a   Olzinski, Alan ^a   Costell, Melissa ^a   Gruver, Susan ^a   Smith, Stephen A ^a   Douglas, Stephen A ^a   Macphee, Colin H ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PADGEM PROTEIN; ROSIGLITAZONE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREMASTER MUSCLE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; ISCHEMIA; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RAT STRAIN; REPERFUSION; RNA ANALYSIS; VASCULAR ENDOTHELIUM;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CELL ADHESION; FATTY ACIDS, NONESTERIFIED; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; LEUKOCYTES; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 27844515113     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.090993     Document Type: Article

References (40)

1. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, and Lusis AJ (1995) Atherosclerosis: basic mechanisms: oxidation, inflammation and genetics. Circulation 91:2488-2496.
2. Boyle PJ (2004) What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? Clin Cardiol 27:IV11-IV16.
3. Chinetti G, Zawadski C, Fruchart JC, and Staels B (2004) Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma and LXR. Biochem Biophys Res Commun 314:151-158.
4. del Zoppo GJ and García JH (1995) Polymorphonuclear leukocyte adhesion in cerebrovascular ischemia, in Physiology and Pathophysiology of Leukocyte Adhesion (Granger DN and Schmid-Schönbein GW eds) pp 408-433, Oxford University Press, New York.
5. Falk E, Shah PK, and Fuster V (1995) Coronary plaque disruption. Circulation 92:657-671.
6. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, and Horikoshi H (1998) Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558.
7. Furie MB and Randolph GJ (1995) Chemokines and tissue injury. Am J Pathol 146:1287-1301.
8. Gavins FNE and Chatterjee BE (2004) Intravital microscopy for the study of mouse microcirculation in anti-inflammatory drug research: focus on the mesentery and cremaster preparations. J Pharmacol Toxicol Meth 49:1-14.
9. Granger DN (1999) Ischemia/reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 6:167-178.
10. Grundy SM, Brewer HB, Cleeman JI, Smith SC Jr, and Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438.
11. Hu E, Liang P, and Spiegelman BM (1996) Adipo-q is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703.
12. Hurst RT and Lee RW (2003) Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 139:824-834.
13. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, and Douglas SA (2004) Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn-Schmiedeberg's Arch Pharmacol 370:238-250.
14. Johns DG, Ao Z, Willette RN, Macphee CH, and Douglas SA (2005) Role of p38 MAP kinase in postcapillary venule leukocyte adhesion induced by ischemia/reperfusion injury. Pharmacol Res 51:463-471.
15. Jucker BM, Schaeffer TR, Haimbach RE, McIntosh TS, Chun D, Mayer M, Ohlstein DH, Davis HM, Smith SA, Cobitz AR, et al. (2002) Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Diabetes 51:2066-2073.
16. Kannel WB and McGee DL (1979) Diabetes and cardiovascular disease: the Framingham study. J Am Med Assoc 241:2035-2038.
17. Kereiakes DJ (1985) Myocardial infarction in the diabetic patient. Clin Cardiol 8:446-450.
18. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, Hama S, Borromeo C, Evans RM, Berliner JA, et al. (2000) Role of peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 87:516-521.
19. Lefer AM, Campbell B, Scalia R, and Lefer DJ (1998) Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. Circulation 98:1322-1328.
20. Lefer DJ (1995) Role of leukocyte adhesion in myocardial ischemia-reperfusion injury, in Physiology and Pathophysiology of Leukocyte Adhesion (Granger DN and Schmid-Schönbein GW eds) pp 393-407, Oxford University Press, New York.
21. Ley K (1996) Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc Res 32:733-742.
22. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, and Goldstein BJ (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662-5667.
23. Murao K, Imachi H, Momoi A, Sayo Y, Hosokawa H, Sato M, Ishida T, and Takahara J (1999) Thiazolidinediones inhibit the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 454:27-30.
24. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, and Kraegen EW (1994) A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210.
25. Pasceri V, Wu HD, Willerson JT, and Yeh ET (2000) Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101:235-238.
26. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, and Glass CK (1998) Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony-stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95:7614-7619.
27. Roberts AW, Thomas A, Rees A, and Evans M (2003) Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol 14:567-573.
28. Robinson SD, Frenette PS, Rayburn H, Cummiskey M, Ullman-Cullere M, Wagner DD, and Hynes RO (1999) Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. Proc Natl Acad Sci USA 96:11452-11457.
29. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126.
30. Scherer PE, Williams S, Fogliano M, Baldini G, and Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749.
31. Smith ML, Sperandio M, Galkina EV, and Ley K (2004) Autoperfused mouse flow chamber reveals synergistic neutrophil accumulation through P-selectin and E-selectin. J Leukoc Biol 76:985-993.
32. Smith SA, Lister CA, Toseland CDN, and Buckingham RE (2000) Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2:363-372.
33. Sundararajan S and Landreth GE (2004) Antiinflammatory properties of PPARγ agonists following ischemia. Drug News Perspect 17:229-236.
34. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, and Pyorala K (1993) Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and nondiabetic subjects. Diabetologia 36:1175-1184.
35. Wagstaff AJ and Goa KL (2002) Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62:1805-1837.
36. Walker AB, Chattington PD, Buckingham RE, and Williams G (1999) The thiazolidinedione rosiglitazone (BRL-46953) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48:1448-1453.
37. Walker AB, Dores J, Buckingham RE, Savage MW, and Williams G (1997) Impaired insulin-induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats. Clin Sci 93:235-241.
38. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, et al. (1996) Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience. J Am Coll Cardiol 28:1661-1669.
39. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, and Jucker BM (2005) Rosiglitazone treatment in Zucker diabetic fatty rats is associated with amelio-rated cardiac insulin resistance and protection from ischemia/ reperfusion-induced myocardial injury. Diabetes 54:554-562.
40. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, et al. (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 104:2588-2594.